Megadalton Solutions

Executive Summary

Megadalton Solutions is a biotechnology company specializing in Charge Detection Mass Spectrometry (CD-MS) for high-resolution characterization of large, complex biomolecules and nanoparticles, including AAV vectors, DNA, VLPs, and vaccines. Founded in 2020 and headquartered in San Francisco, the company leverages AI/ML for data analysis and interpretation to support drug development and manufacturing. As a private firm, Megadalton Solutions addresses a critical need in the gene therapy and vaccine industries for accurate mass and purity measurements of large analytes, where traditional mass spectrometry falls short. The company's services are poised to become essential as the demand for advanced analytics grows with the increasing number of gene therapy and vaccine candidates in clinical pipelines.

Upcoming Catalysts (preview)

• Q3 2026Strategic partnership with a top gene therapy developer60% success
• Q4 2026Publication of benchmark CD-MS data demonstrating superiority over alternative methods80% success
• Q2 2027Expansion of service offerings to include lipid nanoparticle characterization50% success